Pulmonx (LUNG) Q3 2026 Earnings Call: Revenue Returns to Growth
Source Tradingkey
Key Takeaways
- Pulmonx reported Q3 2026 worldwide revenue of $22.8 million, up 6% year over year and marking its first return to global year-over-year growth since management rejoined the company.
- U.S. revenue rose 7% to $14.9 million, supported by improved commercial execution, substantially filled sales territories and eight new treating centers.
- International revenue increased 5% to $7.9 million, or 6% in constant currency. Excluding China, international revenue grew approximately 9%.
- Gross margin improved to 76% from 75%, while operating expenses declined 18% to $24.9 million.
- Adjusted EBITDA loss narrowed nearly 60% to $3.5 million from $8.2 million. Net loss improved 40% to $8.4 million.
- Management reiterated full-year 2026 revenue guidance of $90 million to $92 million and expects gross margin of approximately 77%.
Key Financial Data
| Metric | Q3 2026 | Q3 2025 | Change / Commentary |
|---|---|---|---|
| Worldwide revenue | $22.8 million | $21.5 million | Up 6% reported and constant currency |
| U.S. revenue | $14.9 million | $14.0 million | Up 7% |
| International revenue | $7.9 million | $7.5 million | Up 5%; up 6% constant currency |
| Gross margin | 76% | 75% | Higher due to sales mix and supply-chain efficiencies |
| Operating expenses | $24.9 million | $30.4 million | Down 18% |
| R&D expenses | $4.9 million | $4.8 million | Slight increase |
| SG&A expenses | $20.0 million | $25.6 million | Down 22% |
| Net loss | $8.4 million | $14.0 million | Loss reduced 40% |
| Net loss per share | $0.19 | $0.34 | Loss narrowed |
| Adjusted EBITDA loss | $3.5 million | $8.2 million | Nearly 60% reduction |
| Cash and cash equivalents | $52.7 million | — | Down $3.2 million from June 30, 2026 |
Business and Operating Performance
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Nasdaq rises 0.82% as Anthropic files for IPO, gold reclaims $4,000 and oil falls. Explore Australia's market outlook ahead of the Fed decision.
CNBC host Jim Cramer says he would buy Goldman Sachs shares after Anthropic filed its initial public offering (IPO) prospectus on Monday, a deal that earns the bank fees as a lead underwriter.Goldman’
Bitcoin is fighting to hold $80,000 after three consecutive weeks of losses. The broader crypto market remains under pressure as weak investor confidence and volatility in global stocks weigh on price
Gold has lost nearly a quarter of its value since the US-Iran war began. On Friday, it briefly fell to $3,975 an ounce before recovering to around $4,020 on Monday.Yet investors have been pouring bill
South Korea’s KOSPI rose 4.53% from Monday’s close to 5,717.30 on Tuesday morning. The jump made the Korea Exchange pause program buying for five minutes, its second brake in six days.The first brake,
